Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels

Figure 2

Kaplan Meier curves for progression free survival and overall survival of metastatic colorectal cancer patients treated by FOLFIRI3-bevacizumab in the first line setting, according to the baseline level of angiopoietin-2. (A) The probability of progression free survival was reported in patients with baseline angiopoietin-2 levels below 5 ng/mL or above 5 ng/mL. (B) The probability of overall survival is shown according to baseline angiopoietin-2 levels. Patients with baseline angiopoietin-2 levels above 5 ng/mL displayed a significantly decreased OS (p = 0.0002).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us